A Decade of Progress & the Gaps That Remain: What Real-World Data Tells Us About Liquid Biopsy Access & Clinician Adoption
10:30 am - Friday 19th March 2027
- Sharing findings from a BLOODPAC study on how liquid biopsy is used in practice, mainly for treatment selection and increasingly for MRD, and where uptake is strongest
- Examining the barriers that remain, including clinician understanding of the tests and unequal access for underserved patient populations
- Considering what these lessons mean for the next stage, as the field moves further into MRD and multi-cancer early detection, and what drug developers and diagnostic companies can do to widen access
